Group 1 received fibrin glue manufactured by the Blood and Tissue Bank of Catalonia , Group 2 received Tissucol ( fibrinogen and thrombin ) , Group 3 received intravenous tranexamic acid , and Group 4 ( control ) had no treatment other than routine hemostasis .